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Of all the aspects of non-alcoholic fatty liver disease (NAFLD), the
slowest advances have occurred in the therapeutic ﬁeld.
Thirty-ﬁve years after its formal description and after 15 years
of intense scrutiny from researchers worldwide, there is still no
approved drug for the treatment of non-alcoholic steatohepatits
(NASH). In the meantime, progress in the understanding of
pathophysiology, diagnosis – both invasive and non-invasive,
epidemiology and even natural history have been substantial
or, at times, spectacular. In contrast, hepatitis C virus (HCV) ther-
apy underwent constant improvement and even before the great
acceleration of the past few years, patients were already being
offered approved therapies that were increasingly more efﬁcient.
What then explains such a slow pace of therapeutic advances
in NASH, and will this change in the near future? Here we will
review commonly-held myths that have diverted attention from
therapy of NASH, obstacles that have slowed down industrial
development of drugs for this indication, and recent achieve-
ments that will create better conditions for drug development
programs. We will also brieﬂy review current knowledge of
non-pharmacological and pharmacological management in this
early era of NASH therapies.
 2015 Published by Elsevier B.V. on behalf of the European
Association for the Study of the Liver. Open access under 
CC BY-NC-ND license.Myths and misconceptions
Several long-held myths have considerably slowed the
development of drugs for non-alcoholic steatohepatits (NASH).
Because non-alcoholic fatty liver disease (NAFLD) implies the
presence of steatosis, and steatosis was historically considered
a benign lesion, many physicians did not perceive NASH as a dis-
ease of concern. It was seen as a generally benign manifestationJournal of Hepatology 20
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able clinical relevance. Most practicing diabetologists did not
see and still do not see their diabetic patients when they develop
cirrhosis or liver-related mortality. This generated a lack of atten-
tion for NASH as a disease worth diagnosing, investigating and
treating. Consequently, most of the new and innovative drugs
intended to correct insulin resistance were developed for a dia-
betic indication. Yet observational studies of large cohorts of dia-
betic patients became available and showed that diabetic
patients can die of liver disease [1,2]. Competing risk from other
causes of death and the slowly evolving course of chronic liver
disease explains why, in absolute values, liver-
related mortality is considerably less frequent than death from
cardiovascular or neoplastic causes. However, having diabetes
still increases the risk of death from cirrhosis to the same or even
a larger extent than that of death from the other associated
diseases [3]. For instance, the standardized mortality ratio for
liver cirrhosis (adjusted for multiple confounders) was 2.33 (CI
1.99–2.73) for men and 2.59 (2.15–3.12) for women, while that
for ischemic heart disease was 2.11 (2.05–2.16) and 2.46 (2.39–
2.53), respectively [4]. It may be anticipated that better preven-
tion of cardiovascular death and improved screening programs
for neoplasia will result in the emergence of increased liver-
related mortality in a population of ageing diabetics. A precedent
for this shift in the causes of death was witnessed during the
AIDS epidemic when a better control of opportunistic infections
allowed chronic viral hepatitis to emerge as a major threat.
Even though patients with diabetes can have cirrhosis of different
etiologies, non-alcoholic, non-viral cirrhosis accounts for most
causes of cirrhosis-related death [3]. Equally relevant, death from
primary liver cancer almost mirrors the rising risk and prevalence
of cirrhosis in diabetics outlined above [5]. These ﬁndings are
important as they demonstrate the existence of the unmet medi-
cal need for effective therapy in patients with NASH, a concept
long overlooked by physicians other than hepatogastroenterolo-
gists from a tertiary care settings. Appreciation of this medical
need is required before the considerable ﬁnancial risk and human
effort needed for successful NASH drug development programs
will be undertaken.
Another misconception that is consubstantial to the view of
NASH simply as a complication of diabetes, is that antidiabetic
drugs, if successful in controlling diabetes will sufﬁce to curb
the course of NASH, hence making NASH-speciﬁc therapy
unnecessary. This argument ignores the fact that most NASH15 vol. 62 j S65–S75
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Fig. 1. Pharmacological targets for therapy of NASH.
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patients do not have uncontrolled diabetes, and that the three
most commonly used drugs in type 2 diabetes, namely
metformin, sulfamides and insulin are totally ineffective for
NASH. Similarly, since most NAFLD patients are overweight, do
not eat healthy diets and do not exercise enough [6,7], many in
the ﬁeld believe that diet and lifestyle modiﬁcations but not
sophisticated pharmacological approaches are a reasonable (and
cheaper and safer) choice. By this reasoning, it would be better
to spend the same effort but only a fraction of the resources
necessary to bring drugs to the market in implementing these
lifestyle changes in NASH patients. However, even in the context
of a clinical trial, in which incentive and monitoring are
maximized, patients are typically unable to sustain the assigned
dietary goals and the initial weight loss [8]. Exceptions to this
observation are rare, although occasionally young patients naive
to medical intervention do achieve the desired weight loss with
ensuing hepatic improvement. By contrast, most patients who
seek hepatological advice have a long history of unsuccessful
attempts at dietary and lifestyle changes [9]. The considerable
effort and resources necessary to increase patient compliance
are beyond the means and expertise of most hepatological
centers [10], and therefore there is little chance for a better
outcome than that achieved by specialists with expertise in
nutrition, diabetes or endocrinology.
Finally, while these conceptual obstacles had started to
subside, a different theoretical concern emerged as a potential
deterrent to the development of speciﬁc drug therapy for
NASH. Speciﬁcally, it was suggested that large clinical trials in
NASH might be impractical because of the requirement of
histological documentation, both for inclusion and for assessing
of therapeutic efﬁcacy. However, recent developments have
again proved this wrong. Several phase 2b trials of reasonably
large sample size have been initiated and recruited fully
(Table 1), showing that the medical need and patient and
caregiver expectations are high enough to overcome the hurdle
of liver biopsy (Fig. 2).Table 1. Recently completed and ongoing randomized controlled trails for NASH.
Agent Treatment arms Duratio
Ethylicosapentate 
(EPA-E) [15]
600 mg vs. 900 mg vs. placebo, 
oral
52 wee
Obethicolic acid [120] 25 mg vs. placebo, oral 72 wee
Simtuzumab (GS 6624) 75 mg vs. 120 mg vs. placebo, 
intravenous
96 wee
Simtuzumab (GS 6624) 200 mg vs. 700 mg vs. placebo, 
subcutaneous
96 wee
GFT 505 80 mg vs. 120 mg vs. placebo, 
oral
52 wee
Liraglutide 1.8 mg OD vs. placebo 48 wee
Losartan 50 mg vs. placebo 2 years
Cenicriviroc 150 mg vs. placebo 2 years
Aramchol 400 mg vs. 600 mg vs. placebo 1 year
⁄www.clinicaltrials.gov accessed on February 9th 2015.
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Even when the myths surrounding drug development in NASH
will have largely disappeared, real obstacles will still stand in
the way. One of these stems from our current level of under-
standing of the pathogenesis of NASH. A multitude of potential
pathogenic pathways along with their regulators have been
described (Fig. 3), all of them able to alter the histologic and
metabolic phenotype of a diet-induced insulin resistant rodent.
Each one of these could be an attractive target for therapy. In fact,
disappointingly, most of these potential pharmacological targets
fail to materialize into human drug candidates either because
of insufﬁcient potency to curb the progression of human disease
or because of alternate or duplicate pathways that rescue the
NASH phenotype. PDE4 inhibitors [11], selective caspase inhibi-
tors [12], resveratrol [13,14], omega 3 fatty acid preparationsn Estimated 
enrolment (pts)
Population specifics Clinicaltrials.gov 
identifier
ks 243 Non-cirrhotics NCT01154985
ks 280 Non-cirrhotics NCT01265498
ks 225 Cirrhosis NCT01672866
ks 225 NCT01672879
ks 270
Advanced fibrosis 
without cirrhosis
Non-cirrhotics NCT01694849
ks 50 Both diabetic and 
non-diabetic patients
NCT01237119
214 NASH with fibrosis NCT01051219
252 NASH with fibrosis, 
no cirrhosis
NTC002217475
240 NASH with 
prediabetes/diabetes 
and overweight/
visceral adiposity
NTC002279524
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Fig. 2. Registered interventional trials for adult NASH. Open studies. Data downloaded from www.clinicaltrials.gov on Feb 9th 2015.
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Fig. 3. A broad overview of the pathogenesis of NAFLD. The disease is usually
initiated by either caloric overload (diet and lifestyle induced) or other potential
mechanisms such as drugs e.g. tamoxifen. The threshold for developing a disease
phenotype is modulated by genetic predisposition which involves both individual
single nuclear polymorphisms (SNPs) and mutations but also the patterns of SNP
distribution along speciﬁc metabolic and cellular pathways. Following disease
initiating events, multiple cellular processes come into play. Some of these tend
to perpetuate disease such as progressive inﬂammation, cell death and ﬁbrogene-
sis. Tissue repair pathways also are activated that tend to restore tissue and
metabolic homeostasis. The balance between disease progression pathways and
tissue healing pathways determine whether progression to cirrhosis occurs.
Behavior is a neglected area of research and can perpetuate disease if a healthy
diet and lifestyle is not incorporated into an affected persons’ way of life to
remove disease initiating factors. Metabolic perturbations can drive both disease
progression as well as tissue repair via metabolic reprogramming.
JOURNAL OF HEPATOLOGY[15], anti-TNF alpha and probiotics, are examples of drugs that
work well only in rodent models of NASH. Related to these
failures is our inability to test the potency of these molecules in
pre-clinical models that faithfully recapitulate in small animals
both the spectrum of liver injury in humans (from steatosis to
cirrhosis and hepatocellular carcinoma) and the associated meta-
bolic conditions including insulin resistance. Some NASH models
do not replicate insulin resistance and related comorbidities (the
methionine/choline deﬁcient model); others are genetic oddities
that have no equivalent in regular human NASH and might be
excessively pathway-dependent (MAT1, PTEN, NEMO deﬁcient
mice, ob/ob and db/db knockout mice lacking leptin and thusJournal of Hepatology 201ﬁbrogenesis); yet others do not fully progress to steatohepatitis
and ﬁbrosis (standard high fat diet or high sucrose diets).
Although reﬁnements of dietary models exist (Western diet, high
fructose, trans fat, atherogenic diet models or a combination
thereof) and allow steatohepatitis and early ﬁbrosis to develop
within an acceptable time frame of several months, their use
for antiﬁbrotic testing in the context of NASH is still not optimal.
It follows that only limited predictions for human efﬁcacy are
achievable through pre-clinical models. Therefore this mandates
early testing in humans, which is a risk multiplier in terms of
ﬁnancial and ethical commitments. To make things worse, most
proof of concept trials in NASH need to rely on evidence of
histological efﬁcacy; the duration and size of such trials do not
provide quick answers on whether a drug candidate for NASH
should move forward. All this considerably complicates the drug
development process.Major breakthroughs and their impact on drug development
An important area of progress has been the identiﬁcation and
better understanding of the roles of the various morphological
lesions in the natural history of NASH. Ludwig et al. [16], who
coined the term ‘‘non-alcoholic steatohepatitis’’ deﬁned it as a
disease that mimics alcoholic hepatitis and may progress to cir-
rhosis. Subsequent publications with variable diagnostic criteria
for NASH described a range of disease severity from inconsequen-
tial to rapidly progressive. This was clariﬁed by Matteoni et al.
[17], who reintroduced the term ‘‘non-alcoholic fatty liver dis-
ease’’, (used occasionally before this) to describe the spectrum
of clinical and pathological severity in relation to progression to
cirrhosis and mortality, which were limited to those whose liver
biopsies had hepatocellular ballooning, Mallory-Denk bodies and/
or ﬁbrosis. Brunt et al. in 1999 [18] proposed a three-grade, four-
stage system to characterize and stratify the histologic lesions.
These advances were further reﬁned in 2005 by the NASH CRN
[19], which provided operational histologic deﬁnitions of
NAFLD and NASH and a morphologic tool to measure histological
changes (i.e. the NAS score). Both are crucial in the context of5 vol. 62 j S65–S75 S67
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clinical trials, as these rely on histology for inclusion and also for
assessing treatment effects. Thus, the term steatohepatitis,
deﬁned histologically by the association of steatosis, lobular
inﬂammation and hepatocyte ballooning with a predominant
centrilobular pattern of distribution has come to be used for a
morphological feature with clinical implications. It has been
associated with a more severe clinical proﬁle, more advanced
insulin resistance and more advanced ﬁbrotic disease than non-
NASH NAFLD [20]. It has also been correlated with increased
mortality and liver-related events [21–23], which provides
justiﬁcation for use as a selection criterion for participants in
drug therapy trials. The NAS score may be used to characterize
the lesions, but it must be remembered that as deﬁned by the
NASH CRN, [24] the diagnosis of steatohepatitis is a matter of pat-
tern of injury and not of a score. Unfortunately, the NAS is not
predictive of clinical outcomes [21,25,26], and therefore changes
in NAS on therapy are probably not an adequate outcome
surrogate. This of course does not mean that it cannot be used
to measure the histological impact of different therapies; it sim-
ply may not be sufﬁcient as a predictor of clinical beneﬁt, and
therefore its use for registration purposes is uncertain.
Recently a new histological classiﬁcation was proposed by a
panel of pathologists from the FLIP consortium. The FLIP algo-
rithm and the SAF score were initially described and validated
in a large population of morbidly obese patients undergoing bar-
iatric surgery [27] and later in a NASH hepatological population
[28]. Clinical correlates with the metabolic proﬁle and disease
severity have also been reported [29], although outcome studies
are not yet available. This classiﬁcation system uses a standard-
ized deﬁnition of the elementary histological lesions and has
been shown to increase agreement for the diagnosis of NASH
between hepatopathologists with different levels of expertise
[28]. It remains to be seen how this will be applied in clinical
trials.
Another major advance is in the regulatory ﬁeld (Table 2).
Both the European and the American drug agencies now agree
that NASH is a valid indication for therapy and as such, it can fol-
low a regulatory path for drug approval. There is a need to
develop therapeutics even in early stage NASH, especially in
those patients at risk of progression [30]. Trial outcomes with
clinical and regulatory value have been deﬁned and are currently
being used in several large trials of new drugs in NASH [30,31].
Given the high unmet medical need, the concept of accelerated
approval followed by conﬁrmation in outcome trials appears
legitimate [30]. This is a big change from the previously heldTable 2. Progress and continuing challenges facing the NASH pipeline.
Challenges Progress
Multiple pathogenic 
mechanisms
Recognition of medical need
Imperfect animal models NASH as an indication for 
therapy accepted
Non-invasive proof of 
principle trials 
Operational pathological 
definition of NASH 
Surrogates for hard outcomes Agreed upon and achievable 
surrogate endpoints 
Surrogates for response on 
therapy
Regulatory path increasingly clear
S68 Journal of Hepatology 201perception of NASH as a disease without a clear regulatory
approval process. By ensuring technical feasibility of the registra-
tion pathway, it will certainly provide a big boost to all stake-
holders in the industry-sponsored drug development programs.
But most importantly, it will provide conﬁdence to patients and
caregivers that therapeutic options will be available to those
who need them.Management of NAFLD: what are the lessons so far?
Diet and lifestyle changes as a treatment for NASH
NAFLD patients have unhealthy dietary intakes characterized by
overconsumption of fructose and soft drinks, lower consumption
of ﬁber, overconsumption of meat, saturated fat and cholesterol,
lower consumption of ﬁsh or omega-3 fatty acids or PUFA, and
low consumption of some vitamins [6,32,33]. A high fructose con-
sumption, possibly industrial fructose only (not fruit fructose)
[34], increases the risk of ﬁbrosis in NASH patients [35]. There
seems to be some controversy, however, as to whether the excess
risk is not in fact conferred by an excess caloric intake (irrespective
of the type of sugars) [36,37] or confounded by an unhealthy life-
style pattern that includes smoking, lack of exercise, diets rich in
fat and poor in ﬁber etc [38]. Well designed, prospective studies
accounting formultiple confounders are necessary to better estab-
lish the epidemiological basis for this association. Nonetheless,
interventional data in animals have shown that while high fat
diet alone only induces steatosis, high fat diet + high sucrose diets
induce steatohepatitis, inﬂammation oxidative stress and ﬁbrosis
[39]. In overweight/obese individuals, dietary fructose speciﬁcally
increases de novo lipogenesis, promotes dyslipidemia, increases
insulin resistance and increases visceral adiposity [40]; other
studies however did not conﬁrm that fructose is metabolically
more deleterious than other sugars like glucose [41].
There are very few RCTs of dietary interventions on liver
injury in NASH patients. In a well conducted but small RCT, 32
NASH patients were randomized to receive complex, intensive
lifestyle intervention or basic education about a healthy lifestyle
(controls) over a 48-week period [42]. The active arm
experienced higher weight loss, more frequent resolution of
steatohepatitis (67% vs. 20%, p = 0.02), and a higher reduction in
the NAS score, an aggregate score of steatosis and NASH
histological activity (p = 0.05 only, possibly due to the small sam-
ple size). Only 40% of participants in the active group achieved a
P10% weight reduction but, importantly, a post-hoc analysis
revealed that a mere 7% weight loss (irrespective of the arm)
was associated with histological improvement [42]. Those are
important proof of concept results demonstrating that weight
loss can result in histological improvement. However, more
research is needed to answer this crucial question: is there a
threshold of histological severity above which mild weight loss
no longer sufﬁces to improve the liver injury? In other words
can severe, ﬁbrotic NASH improve signiﬁcantly with only diet
and lifestyle measures? The only indication of liver disease sever-
ity in the two treatment arms of the trial by Promrat et al. is a
mean NAS score between 4.4 and 4.9 and a mean ﬁbrosis score
of 1.4 to 1.7. However, it is well established that massive weight
loss following bariatric surgery can result in spectacular
histological improvement, including partial reversal of cirrhosis5 vol. 62 j S65–S75
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[43,44]. In morbidly obese patients, bariatric surgery can improve
histology across the board, including resolution of NASH in 75% of
cases and reduction of ﬁbrosis in 34% of cases after a long follow-
up [45]. This level of improvement, however, cannot be achieved
with diet and lifestyle measures. Interestingly, bariatric surgery
might also correct the pro-inﬂammatory state associated with
obesity [46]. Indeed massive weight loss reduces adipose tissue
pro-inﬂammatory mediators such as TNFa and IL6, which results
in reduced expression of hepatic SOCS3, thus improving hepatic
insulin resistance and inhibiting hepatic inﬂammation [47].
The only other RCT of dietary intervention and exercise in
NAFLD was conducted in type 2 diabetics and did not have
histological endpoints [48]. It showed improvement in hepatic
fat content as measured by magnetic resonance spectroscopy
and a reduction in the incidence of NAFLD during follow-up.
However, it is doubtful that this resulted in improvement of the
other lesions of steatohepatitis including hepatic inﬂammation,
since there was no difference in aminotransferase levels [48].
Despite the absence of well conducted trials in NAFLD, the
relation between weight reduction and improvement in ALT
[49] and at least some of the histological features of NASH
[42,50] is now accepted. Even in the absence of speciﬁc NASH
trials, a wealth of information on diets, hepatic fat and metabolic
alterations exists and this can prove useful for NAFLD/NASH
patients. A remarkable ﬁnding was that relatively small amounts
of weight loss result in signiﬁcant reductions in liver fat and hep-
atic insulin resistance improvement [51] although no data on
other histological endpoints exist. The most important factor in
dietary interventions seems to be caloric restriction. It is the main
driver for weight loss and visceral adiposity, subcutaneous fat and
liver fat reduction [52]. Themacronutrient composition of the diet
does not matter for the weight loss outcome, as long as weight
loss is achieved, and this usually means that long-term compli-
ance is key [52,53]. Some data point towards an early beneﬁcial
effect of a carbohydrate-deﬁcient diet on hepatic fat and insulin
sensitivity [54,55]. This might not make a difference however in
the long-term when overall weight loss is achieved and insulin
resistant sites other than the liver are studied [54]. Other studies
did not conﬁrm differences between low carbohydrate and low fat
diets as long as they are both calorie restricted [56]. Recently it
was suggested, within a randomized trial, that a Mediterranean
diet which is very rich in monounsaturated fatty acids and rich
in polyunsaturated fatty acids can reduce liver fat and improve
hepatic insulin resistance even without weight loss [57].
Although in a clinical trial setting these dietary interventions
might reach some of the assigned endpoints, most will fail both
at the individual level and at the population level. These trials
are largely an academic activity hardly applicable to real-life;
patients will relapse once the intervention is over as they, or their
physicians cannot sustain the major intervention efforts it
requires. Weight loss among participants in diet trials will at best
average 3 to 4 kg after 2 to 4 years [58] even less among poor and
uneducated people who are hit hardest by obesity [59]. Evenmore
worrisome is that individual treatments are powerless against an
obesigenic environment that offers so many high-calorie foods
and labor-saving devices [60]. Therefore, at a population level,
only community interventions with total-environment changes
might prove successful. In two small towns, a large community-
based effort to prevent school children from being overweight
has reduced the prevalence by half, a result no isolated dietary
intervention can achieve in a sustainable manner [61].Journal of Hepatology 201Physical activity as an adjunctive therapy
Half of NAFLD patients are inactive and that includes almost a
third that have virtually no physical exercise [62]. This has been
observed both in the US and in European populations [7]. The
beneﬁts of exercise are well established and range from a reduc-
tion in the risk of type 2 diabetes, hypertension, dyslipidemia,
the metabolic syndrome and insulin resistance to a reduction in
all-causemortality and in cancermortality [63,64]. Meta-analyses
have shown that exercise alone signiﬁcantly reduces the hepatic
fat content, a beneﬁt occurring with minimal or no weight loss
[65]. The effect on other histological lesions of NASH is unknown
although preliminary data suggest an effect on hepatic markers of
apoptosis [66]. Exercise also reduces visceral adipose tissue and
plasma free fatty acids [67]. It reduces by a third the likelihood
of having NASH [62] or advanced ﬁbrosis in the context of
NASH. Clearly, physical activity follows a dose-effect relationship
[63] and vigorous (running), rather thanmoderate (brisk walking)
exercise carries the full beneﬁt, including for NASH and ﬁbrosis
[62]. Unfortunately NAFLD patients have a low compliance with
physical exercise as they have high rates of fatigue which is
associated with inactivity and daytime sleepiness [68].
Resistance training that promotes musculoskeletal ﬁtness rather
than cardiovascular ﬁtness should also be implemented. It may
be accessible to more patients, as it places less of a demand on
the cardiorespiratory system [69]. In NAFLD, resistance exercise
reduces liver fat (sometimes to the point where NAFLD resolves)
and improves glucose control and insulin sensitivity and
promotes fat oxidation, despite no weight loss and no impact on
visceral fat [70]. Overall, NAFLD patients that beneﬁt most from
exercise intervention are those that have some level of cardiores-
piratory ﬁtness at baseline [71]. Those are actually a minority,
since altered cardiorespiratory ﬁtness is common in NAFLD
patients [72]. Again, this casts doubt on the ability of non-
pharmacological interventions to be effective in most NASH
patients.
While engaging in physical exercise is beneﬁcial, avoiding
sedentary time is equally important. Sedentary time increases
all-cause mortality independent of physical activity [73] and pre-
dicts higher levels of insulin resistance [74]; conversely, reducing
sitting time improves insulin sensitivity [75]. No speciﬁc studies
are available in NAFLD but since this only entails minimal disrup-
tion of daily activities by short bouts of walking it should be part
of lifestyle changes in all NAFLD patients.
Akin to dietary measures it is also important to set realistic
goals for exercise as well, since any engagement in physical exer-
cise and any increase over previous levels of exercise is better
than continuing inactivity [76]. Pragmatic approaches combining
progressive increases in aerobic exercise and resistance training
together with reduced sedentary time [77] are preferable and
should be implemented on a case by case basis.Where do we stand with pharmacological therapies?
An ideal drug candidate for NASH should reduce hepatic inﬂam-
mation and liver cell injury, should correct the underlying insulin
resistance and should have antiﬁbrotic effects (Fig. 1). However,
primarily ‘‘anti-NASH’’ drugs that have no direct antiﬁbrotic
effect could, theoretically, result in a subsequent reduction of
ﬁbrosis if a sustained resolution of NASH is achieved.5 vol. 62 j S65–S75 S69
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Conversely, purely antiﬁbrotic drugs with no anti-NASH activity
and no interference with insulin resistance will leave the triggers
for ﬁbrogenesis intact. Therefore, even if an antiﬁbrotic is effec-
tive, efforts to curb the underlying pro-ﬁbrotic condition must
be considered.
Insulin sensitizers
It is no surprise that most attempts to treat NASH have focused
on insulin sensitizers. Insulin resistance is a near constant ﬁnding
in primary NASH. It is the main driving force behind excessive fat
accumulation in the liver but may also play a role in the initiation
and perpetuation of steatohepatitis and ﬁbrosis progression. The
main source of free fatty acids reaching the liver is an uncon-
trolled release from insulin resistant adipose tissue. A current
model for the pathogenesis of NASH is centered on lipotoxicity
[78], which states that the inﬂux of fatty acids and their deriva-
tives through the liver induces apoptosis, oxidative stress,
endoplasmic reticulum stress, activation of pro-inﬂammatory
pathways and ultimately liver cell injury [79].
Of all tested drugs, glitazones are those with the best evi-
dence-based data and also with the strongest pathogenesis-based
rationale for treatment of NASH (reviewed in [80]). Glitazones
promote differentiation of insulin resistant large pre-adipocytes
into small, proliferative, insulin sensitive adipocytes [81–83].
Upon induction of lipoprotein lipase and of a large set of lipogenic
genes [84], glitazones enhance fatty acid uptake and synthesis in
the adipose tissue [85]; this diverts the non-esteriﬁed free fatty
acid load towards adipocytes instead of other organs such as liver
and muscle. Ultimately, inappropriate fat storage in organs other
than adipose tissue is reduced, with subsequent improvement in
insulin sensitivity despite the expansion in fat mass. Glitazones
also upregulate adiponectin [86], an insulin-sensitizing and
anti-steatogenic adipokine, which increases fatty acid beta-
oxidation in liver and muscle [87]. PPARc agonists also exert
anti-inﬂammatory effects on Kupffer cells, which might be
indicative of direct hepatoprotective effects.
Pioglitazone is the best studied pharmacological agent in
NASH. The largest trial so far, the PIVENS trial, compared piogli-
tazone at a low dose of 30 mg/day vs. vitamin E (800 IU/day) vs.
placebo for 2 years in patients without full-blown diabetes [88].
Pioglitazone improved all individual histological features (except
for ﬁbrosis) and achieved resolution of steatohepatitis – (cur-
rently considered the optimal surrogate endpoint in NASH trials
[31,89]) more often than placebo. The histological beneﬁt
occurred together with ALT reduction and partial correction of
insulin resistance [88]. It has been suggested [90], but not con-
ﬁrmed [91], that glitazones strongly improve adipose tissue insu-
lin resistance, which correlates with the reduction in steatosis
and necroinﬂammation [90]. Similar efﬁcacy results were
reported in two smaller randomized trials of shorter duration
[92,93]. It is not clear whether the efﬁcacy of pioglitazone
depends on the degree of insulin resistance or the diabetic status.
The optimal duration of therapy is also a largely unsettled issue.
A prolonged, three-year therapy with rosiglitazone did not result
in additional histological improvement beyond that obtained in
the ﬁrst year [94], suggesting a plateau effect of hepatic histologi-
cal improvement once the maximum insulin-sensitizing beneﬁt
is obtained. This was not formally tested with pioglitazone. On
the other hand, beneﬁcial effects seem to be short-lived after
treatment discontinuation. Both ALT and HOMA values returnS70 Journal of Hepatology 201to baseline starting 3 months after discontinuation, and in the
few patients with one year follow-up biopsies, steatohepatitis
recurred despite on-treatment clearance [95].
The side effect proﬁle of glitazones is of concern, particularly
weight gain, which is not always reversible upon discontinuation.
Bone fractures in women seem to be due to an increased rate of
bone loss. Congestive heart failure is a rare complication, yet it
warranted a black-box warning. Concerns about an increased risk
of bladder cancer with pioglitazone [96,97] were not conﬁrmed
by recent data collected in one million type 2 diabetic individuals
from six cohorts around the world [98]. Despite the safety and
tolerability proﬁle and while waiting for better options, pioglita-
zone can be used for NASH. In diabetic patients with an indication
of therapy for NASH, a further reason to use pioglitazone is that
this drug is also indicated for glycemic control.
Metformin is an oral biguanide approved for use in type 2 dia-
betes in which it acts as an insulin-sensitizing agent, reducing
hepatic glucose production and increasing peripheral glucose uti-
lization [99]. Metformin reduces the hepatic endogenous glucose
production by activating AMP-activated protein kinase [100] but
also by inhibiting the mitochondrial glycerophosphate dehydro-
genase shuttle with subsequent changes in redox state [101].
Although metformin is a safe drug, it is not recommended for
the treatment of NASH [102], as it has shown no effect on liver his-
tology other than the occasional improvement in patients that lost
weight. This inefﬁcacy of metformin despite its insulin-sensitizing
effectmay be due to itsweak anti-steatogenic effect and the lack of
induction of circulating adiponectin compared to glitazones,
although this has not been tested over long-term exposure
[103]. Limited pre-clinical data support an anti-tumorigenic effect
of metformin on liver cancer [104,105] but the clinical demonstra-
tion of a reduced rate of HCC in humans is only suggestive and lim-
ited to retrospectively collected data [105,106], which is subject to
confounding by treatment assignment bias. In non-diabetic chil-
dren with NASH, metformin improved ballooning but not amino-
transferases, HOMA or any other histological outcome [107].
Among existing therapies for type 2 diabetes, incretin mimet-
ics which are glucagon-like peptide-1 receptor (GLP-1R) agonists
hold promise for the treatment of NASH. GLP, a peptide product
of the L cells of the small intestine and proximal colon stimulates
insulin secretion from the b cells and inhibits glucagon secretion
from the a cells in a glucose dependent manner, but also
enhances satiety and delays gastric emptying. GLP-1R agonists
have a much longer half-life than natural GLP allowing a once
daily administration. GLP-1R are functional in hepatocytes and
in vitro studies have shown an induction in PPARa and c expres-
sion upon GLP-1R agonist binding, which resulted in increased
disposal of hepatocyte fatty acids by beta-oxidation and lipid
export [108,109]. This was conﬁrmed in vivo with improvement
of steatosis in exendin-treated mice [110]. Moreover, GLP-1R
agonists could improve hepatic insulin sensitivity [109] by
increasing phosphorylation of key signaling pathways such as
AKT and PKC-f [111]. In patients with diabetes, liraglutide at
the high dose of 3 mg/day, currently FDA approved for the treat-
ment of obesity, reduced ALT and showed a trend towards
improvement of steatosis [112]. These effects were mainly
mediated by weight loss and better glucose control [112]. Other
potentially beneﬁcial effects in humans for the treatment of
NASH are reduced de novo lipogenesis, and improved adipose tis-
sue lipolysis and inﬂammation [113]. Data on histological efﬁcacy
are eagerly awaited.5 vol. 62 j S65–S75
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Novel therapies with insulin-sensitizing effects but also anti-
inﬂammatory and antiﬁbrotic actions are under development.
Bile acids are now believed to play a crucial role in regulating
liver and metabolic homeostasis. Their action is mediated
through nuclear hormone receptors such as the farnesoid X
receptor (FXR) and TGR5. FXR activation has a wide range of
metabolic effects: it improves both glucose metabolism and
peripheral insulin sensitivity [114]; it also reduces lipogenesis
and enhances fatty acid b-oxidation [115]. Interestingly, FXR
activation has also anti-inﬂammatory actions [116,117] with
resultant protection against liver inﬂammation and ﬁbrosis in
the methionine/choline deﬁcient model of NASH [118].
Obeticholic acid (OCA) is a synthetic bile acid with picomolar
agonistic activity on FXR. A small randomized trial in type 2 dia-
betic patients with NAFLD showed an improvement in insulin
sensitivity as measured by euglycemic clamp, a modest but
dose-related weight loss, and a reduction in ALT levels [119].
Recently, the FLINT trial compared 25 mg of OCA vs. placebo over
72 weeks of therapy in non-cirrhotic NASH patients [120] and
reported improvement in all lesions of steatohepatitis including
ﬁbrosis. The therapeutic phase of the trial was stopped early,
partly because a preplanned interim analysis showed improved
histology in more patients on OCA (50 [45%] of 110) than on pla-
cebo (23 [21%] of 109). Importantly, there was a reduction in
ﬁbrosis score (one stage) in 35% of OCA-treated patients vs. 19%
in the placebo arm. These are encouraging data that deserve con-
ﬁrmation in larger trials. Side effects were pruritus and an
increase in LDL cholesterol; studies are underway to fully under-
stand whether the lipid changes are associated or not with
increased cardiovascular risk.
Another innovative insulin sensitizer is GFT505, a dual PPARa/d
agonist that undergoes extensive enterohepatic cycling and is liver
targeted [121]. PPARd activation emerged as a potent metabolic
regulator that induces hepatic fatty acid b-oxidation, inhibits
hepatic lipogenesis [122], reduces hepatic glucose production
and improves hepatic inﬂammation [123,124]. Human studies
performed in abdominally obese, insulin resistant patients, with
or without diabetes have shown that GFT505 improves hepatic
and peripheral insulin sensitivity, dyslipidemia, inﬂammatory
markers and liver function tests [125,126]. Animal data conﬁrmed
the hepatoprotective effects of GFT505 in dietary models of NASH
or ﬁbrosis with, in particular, a reduction in steatosis, hepatic
inﬂammation andpro-inﬂammatory genes [127]. Importantly, this
compound exhibited antiﬁbrotic properties in ﬁbrosismodels that
were independent of metabolic and insulin resistance abnormali-
ties [127], thereby suggesting a universal antiﬁbrotic potency in
rodents. Based on these promising results, a large, phase 2b, ran-
domized controlled trial is now underway in NASH patients. A
good safety proﬁle is anticipated from earlier phase 2a studies
and, in particular, from the lack of PPARc agonistic activity.
Hepatoprotective agents
Vitamin E is a fat soluble compound that is present in the
phospholipid bilayer of cell membranes, where it protects from
oxidative damage induced by free radicals. Vitamin E prevents
liver injury by protecting against mitochondrial toxicity and
blocking intrinsic apoptotic pathways [128,129]. It might also
have non-antioxidant properties, for instance by altering cell
signaling, gene expression [130] or down-regulating NF-kB-
dependent inﬂammatory pathways [131]. Vitamin E has beenJournal of Hepatology 201tested in the above mentioned PIVENS trial at 800 IU daily. It
signiﬁcantly improved steatosis, inﬂammation and ballooning
and induced resolution of NASH in 36% of patients (21% in the
placebo group). The reduction in ALT was well correlated with
histological improvement, and histological non-responders, for
the most part, did not have a reduction in ALT [132]. The results
were only partly reproduced in the paediatric TONIC trial where
vitamin E failed to reduce aminotransferases, steatosis and
inﬂammation but improved ballooning and cleared NASH in
58% of the patients (28% in the placebo group). These results
stand in contrast to previous trials that were mostly negative in
both adults and children. Concerns about long-term safety of
vitamin E exist, mainly an increase in overall mortality [133], in
the incidence of hemorrhagic stroke [134] and in that of prostate
cancer in males older than 50 years [135]. However, the increased
risk of prostate cancer only becomes signiﬁcant after three years
of exposure [135]. Vitamin E may be used in NASH patients with
aggressive disease, although additional studies demonstrating its
efﬁcacy are needed before ﬁrm recommendations for use can be
made. In non-diabetic children treated for 96 weeks, vitamin E
induced resolution of NASH and improvement in ballooning more
often than placebo although there was no effect on steatosis,
inﬂammation or ﬁbrosis [107]. Surprisingly, a 2 year study
comparing vitamins E and C vs. tailored diet and lifestyle inter-
ventions did not show an advantage of the vitamin regimen per-
haps because similar weight loss occurred in both groups [136].
Many other compounds have been tested for NASH with
either inconclusive or negative results and most in small trials
(reviewed in [137]). New compounds are in development in large
multicentre, international RCTs either as anti-inﬂammatory
agents (cenicriviroc a CCR2-CCR5 antagonist), metabolic mod-
ulators (aramchol, a fatty acid-bile acid conjugate) or antiﬁbrotics
(simtuzumab, a humanized, anti-lysyl-oxidase 2 monoclonal
antibody).Challenges for the near future
Probably the most urgent need in the ﬁeld of NASH is the discov-
ery of biomarkers that would help diagnose and monitor disease
progression. In primary-care settings where numerous
individuals are exposed to metabolic risk factors, biomarkers
should identify those at high risk of NAFLD-related liver disease.
In secondary- and tertiary-care settings, biomarkers should
identify those with advanced/severe NASH. Not only will this help
provide prognostic information but it will also select those in need
for speciﬁc, liver-directed therapy. Equally important, biomarkers,
or for that matter, imaging methods, should reliably monitor dis-
ease progression. This might require more than just the knowl-
edge of ﬁbrosis stage. Recent reports have documented the
transition from NAFL to NASH, sometimes with advanced ﬁbrosis
[138,139]. This justiﬁes long-term follow-up, even in patients
without steatohepatitis at diagnosis, and especially if metabolic
risk factors persist or worsen. Finally there is a strong need to pre-
dict the response to pharmacological or non-pharmacological
interventions. Ongoing trials are already striving to identify com-
panion tests for speciﬁc molecules that will eventually eliminate
the need for histology to document efﬁcacy. A timely prediction
of response to drugs will shorten the timelines for completing
clinical trials and will reduce useless drug exposure in patients
that are non-responders.5 vol. 62 j S65–S75 S71
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Whatever the fate of ongoing clinical trials, none of the
molecules under active investigation are expected to provide
signiﬁcant improvement of NASH in more than a minority of
patients. Therefore continuous research and discovery programs
should aim at identifying new targets for therapy and eventually
combine those that target synergistic pathways. Individualized
therapy based on severity of disease and treatment response
might be a reality as soon as anti-NASH and antiﬁbrotic agents
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